Add
AGEN to Portfolio
Set Alert
Email to a
Friend
| |||
|
|
Quotes & Info
|
| AGEN > SEC Filings for AGEN > Form 8-K on 4-Nov-2009 | All Recent SEC Filings |
4-Nov-2009
Regulation FD Disclosure, Financial Statements and Exhibits
On November 4, 2009, Antigenics Inc. announced that GlaxoSmithKline's (GSK) Phase III malaria vaccine clinical trial, containing Antigenics' QS-21 Stimulon® adjuvant, has enrolled more than 5,000 children to date and is expected to involve up to 16,000 children. The pivotal efficacy study of RTS,S, the world's most clinically advanced malaria vaccine, is ongoing in seven African countries.
The QS-21 adjuvant is a key component in several of GSK's prophylactic and therapeutic vaccines, including RTS,S. Under the terms of the license and supply agreements between the companies, Antigenics will receive payments from GSK contingent upon achievement of successful milestones and from royalties on net sales for a period of at least 10 years after the first commercial sale.
The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this current report on Form 8-K.
(d) Exhibits
The following exhibit is furnished herewith:
99.1 Press Release dated November 4, 2009
|
|